NCT03856099 is a Phase 2 clinical trial of TTAC-0001 in Recurrent Glioblastoma, sponsored by PharmAbcine.

Who is sponsoring NCT03856099?

NCT03856099 is sponsored by PharmAbcine.

What drugs are being tested in NCT03856099?

Interventions in NCT03856099: TTAC-0001.

What condition does NCT03856099 study?

NCT03856099 studies Recurrent Glioblastoma.

Is NCT03856099 still recruiting?

NCT03856099 is currently terminated. Last updated 18 August 2022.

Last reviewed 2022-08-18 · How we verify

NCT03856099

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Terminated Phase 2 Last updated 18 August 2022

What this trial tests

Phase 2 trial testing TTAC-0001 in Recurrent Glioblastoma in 19 participants. Terminated before completion.

Timeline

13 November 2019

Primary endpoint
15 July 2022

15 July 2022

Quick facts

Lead sponsor	PharmAbcine
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	13 November 2019
Primary completion	15 July 2022
Estimated completion	15 July 2022
Sites	3 locations across United States, Australia

Drugs / interventions tested

TTAC-0001 — full drug profile →

Conditions studied

Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

PharmAbcine — full company profile →

Who can join

18 and older, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment.
Delgado-Martín B, Medina MÁ. · · 2020 · cited 129× · PMID 32382477 · DOI 10.1002/advs.201902971
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging.
Li D, Patel CB, Xu G, Iagaru A, et al · · 2020 · cited 30× · PMID 33193439 · DOI 10.3389/fimmu.2020.592389
Angiogenesis in Glioblastoma-Treatment Approaches.
Nowacka A, Śniegocki M, Smuczyński W, Bożiłow D, et al · · 2025 · cited 20× · PMID 40136656 · DOI 10.3390/cells14060407
Anti-angiogenic therapies in the management of glioblastoma.
Schulte JD, Aghi MK, Taylor JW. · · 2021 · cited 16× · PMID 32389001 · DOI 10.21037/cco.2020.03.06
Understanding the Role of Endothelial Cells in Glioblastoma: Mechanisms and Novel Treatments.
Hovis G, Chandra N, Kejriwal N, Hsieh KJ, et al · · 2024 · cited 11× · PMID 38892305 · DOI 10.3390/ijms25116118

Verify or expand the search:

Other trials of TTAC-0001

Trials testing the same drug.

NCT03033524 — Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma · Phase 2 · completed

Other recruiting trials for Recurrent Glioblastoma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting

Other PharmAbcine trials

Trials by the same sponsor.

NCT05957081 — Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 · Phase 1 · recruiting
NCT05953012 — Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration · Phase 1 · completed
NCT04986852 — Olinvacimab With Pembrolizumab in Patients With mTNBC · Phase 2 · terminated
NCT03722342 — TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma · Phase 1 · unknown
NCT03720431 — TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03856099 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PharmAbcine
Last refreshed: 18 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03856099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing